[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.180.70. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Correction
November 1998

Error in Figure

Arch Gen Psychiatry. 1998;55(11):1052. doi:10.1001/archpsyc.55.11.1052

In the article titled "Depressive Signs and Symptoms in Schizophrenia: A Prospective Blinded Trial of Olanzapine and Haloperidol," published in the March 1998 issue of the ARCHIVES (1998;55:250-258), an error appeared in Figure 2 on page 254. The bars for olanzapine and haloperidol should have been separated, the lighter bar representing haloperidol-associated change, and the darker bar, olanzapine-associated change. Figure 2 is reprinted correctly here.

Figure 2.
The individual Montgomery-Asberg Depression Rating Scale (MADRS) item contributions to the total score change. Those with an asterisk represent significant between-treatment differences (items 1-4 and 7), which all favored olanzapine. Asterisk indicates P<.05, F test of treatment effect using analysis of variance.

The individual Montgomery-Asberg Depression Rating Scale (MADRS) item contributions to the total score change. Those with an asterisk represent significant between-treatment differences (items 1-4 and 7), which all favored olanzapine. Asterisk indicates P<.05, F test of treatment effect using analysis of variance.

×